| 发明名称 | RNAi modulation of ApoB and uses thereof | ||
| 摘要 | The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides. | ||
| 申请公布号 | US9187747(B2) | 申请公布日期 | 2015.11.17 |
| 申请号 | US201314058679 | 申请日期 | 2013.10.21 |
| 申请人 | Alnylam Pharmaceuticals, Inc. | 发明人 | Soutschek Juergen;Vornlocher Hans-Peter;Hadwiger Philipp;Elbashir Sayda |
| 分类号 | C07H21/02;C07H21/04;A61K31/70;C12N15/113;A61K31/7105;A61K31/718;C12N5/00;C12Q1/68 | 主分类号 | C07H21/02 |
| 代理机构 | Fenwick & West LLP | 代理人 | Fenwick & West LLP |
| 主权项 | 1. An isolated iRNA agent comprising a sense strand and an antisense strand, wherein the agent is targeted to at least 15 contiguous nucleotides of the target sequence of AL-DUP 5098 (SEQ ID NO:155 and SEQ ID NO:156) within the ApoB mRNA, and wherein each strand is between 15 and 30 nucleotides in length. | ||
| 地址 | Cambridge MA US | ||